The current state of the patients’ management with nasal polyposis and allergic rhinitis has become the basis for a deep analysis of the currently available data on the prevalence of diseases (with a focus on severe forms), as well, available possibilities and disadvantages of conservative therapy are considered. The approaches to assessing the severity and control of diseases and the influence of an uncontrolled course on the quality of the patients’ life are presented. Particular attention is paid to a new class of drugs – monoclonal antibodies, which might change the patients’ treatment paradigm of severe uncontrolled course of allergic rhinitis and nasal polyposis. The efficacy and safety issues of immunobiological therapy are discussed on the example of the IgE-targeted medicine omalizumab. The potential place of the drug in the treatment of the mentioned above forms of nasal polyposis and allergic rhinitis is indicated.

No abstract